Saving Lives Through Innovation
Chrysalis BioTherapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of treatments for serious respiratory disorders and acute radiation exposure
Chrysalis BioTherapeutics, Inc.
Chrysalis is pioneering the use of natural regenerative peptides to restore vascular function and activate normal stem cell populations where they exist in the body to accelerate tissue repair and prevent damaging effects of trauma, disease, ischemia, and radiation exposure
There is an urgent unmet clinical need for a drug to prevent mortality caused by acute respiratory distress syndrome (ARDS) caused by COVID-19 and non-COVID-related infection, inflammation, or traumatic injury. The immediate target indication for TP508 is to treat mild to moderate ARDS patients to reduce mortality and reverse systemic effects on lung, heart, brain and kidney such as that seen in long-COVID (long-haulers) patients
IND Enabling Studies/cGMP Manufacturing